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Summary box
 ► Severe acute respiratory infections (SARI) are one of 
the leading global causes of mortality and the most 
likely syndrome associated with future pandemics.
 ► Research preparedness for future pandemics in-
cludes demonstrating global collaboration, as well 
as understanding the baseline clinical features of 
the disease.
 ► Baseline severity of illness scores are highly predic-
tive of outcomes.
 ► Global collaboration across regions with stan-
dardised data collection is feasible, and rapid dis-
semination of data during a future pandemic through 
this platform holds great promise.
 ► Future research should refine data elements collect-
ed and expand sampling at disparate regions to im-
prove research preparedness for future pandemics.
AbSTrACT
Severe acute respiratory infections (SARI) remain one of 
the leading causes of mortality around the world in all age 
groups. There is large global variation in epidemiology, 
clinical management and outcomes, including mortality. 
We performed a short period observational data collection 
in critical care units distributed globally during regional 
peak SARI seasons from 1 January 2016 until 31 August 
2017, using standardised data collection tools. Data were 
collected for 1 week on all admitted patients who met 
the inclusion criteria for SARI, with follow-up to hospital 
discharge. Proportions of patients across regions were 
compared for microbiology, management strategies and 
outcomes. Regions were divided geographically and 
economically according to World Bank definitions. Data 
were collected for 682 patients from 95 hospitals and 23 
countries. The overall mortality was 9.5%. Of the patients, 
21.7% were children, with case fatality proportions of 
1% for those less than 5 years. The highest mortality 
was in those above 60 years, at 18.6%. Case fatality 
varied by region: East Asia and Pacific 10.2% (21 of 206), 
Sub-Saharan Africa 4.3% (8 of 188), South Asia 0% (0 of 
35), North America 13.6% (25 of 184), and Europe and 
Central Asia 14.3% (9 of 63). Mortality in low-income 
and low-middle-income countries combined was 4% as 
compared with 14% in high-income countries. Organ 
dysfunction scores calculated on presentation in 560 
patients where full data were available revealed Sequential 
Organ Failure Assessment (SOFA) scores on presentation 
were significantly associated with mortality and hospital 
length of stay. Patients in East Asia and Pacific (48%) 
and North America (24%) had the highest SOFA scores of 
>12. Multivariable analysis demonstrated that initial SOFA 
score and age were independent predictors of hospital 
survival. There was variability across regions and income 
groupings for the critical care management and outcomes 
of SARI. Intensive care unit-specific factors, geography 
and management features were less reliable than 
baseline severity for predicting ultimate outcome. These 
findings may help in planning future outbreak severity 
assessments, but more globally representative data are 
required.
InTroduCTIon
Lower respiratory infections are the leading 
infectious cause of death worldwide.1 Severe 
acute respiratory infection (SARI) is an acute 
respiratory infection with fever, cough and 
hospitalisation and is used for surveillance 
in acute care settings globally. Organ-specific 
support is often required, with high attrib-
utable mortality.2 A better understanding of 
global variability in the epidemiology and 
care provided for critically ill patients with 
SARI is lacking.
The SPRINT-SARI (Short Period prev-
alence Study of Severe Acute Respiratory 
Infection) programme leverages the function 
of existing networks that have been estab-
lished to provide a rapid research response in 
the event of a future respiratory outbreak of 
public health importance.
As part of the SPRINT-SARI and Inter-
national Severe Acute Respiratory and 
Emerging Infection Consortium networks 
of clinical research preparedness for future 
SARI outbreaks, we are collecting period 
prevalence data for SARI across disparate 
research networks and hospitals around the 
world. The primary aim in establishing this 
network is to create a global collection of 
hospitals, from disparate regions and hospital 
types, primed to collect observational data on 
patients with SARI in a future outbreak.3 This 
involves annual data collection rehearsals to 
both better understand epidemiology over 
time and to maintain institutional familiarity 
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with the process of clinical research data collection.4 
The importance of preapproved protocols for research 
during emergencies has been well demonstrated.5 6 This 
is the first time that the global readiness to conduct such 
outbreak-related research has been repeatedly tested 
using a common data set among many global regions.
In addition to research preparedness for future 
outbreaks, documenting variation in epidemiology, 
management and outcomes of patients with SARI across 
regions is the first step towards standardising care, 
improving outcomes, and ensuring that interventional 
studies are performed on the background of optimal, 
standardised clinical care. We present combined results 
from the first two seasons of data collection for this 
programme during 2016–2017, where the primary circu-
lating respiratory viruses were influenza A (H3N2) and 
A(H1N1)pdm09.7 8
roll-ouT of dATA ColleCTIon InfrASTruCTure
design
SPRINT-SARI is an annual period prevalence study 
enrolling newly admitted patients with SARI to partici-
pating intensive care units or hospital wards where inten-
sive care units were not accessible. All patients admitted 
over a 1-week period during the peak respiratory infec-
tion season in northern and southern hemispheres 
were enrolled. Hospitals and intensive care units were 
sampled through convenience, due to their participation 
in prior studies or involvement with ongoing research 
networks. This study was registered at  ClinicalTrials. gov 
(NCT02498587).
Patients
Eligible patients were those admitted to the relevant 
hospital unit of interest if they met the following inclu-
sion criteria: suspected or proven acute respiratory infec-
tion with onset within the past 14 days, with one or more 
of the following: fever, cough, dyspnoea or tachypnoea. 
There were no exclusion criteria. Consent was obtained 
where deemed appropriate per local ethics boards, 
and waived at other institutions due to the routine and 
anonymised nature of the data collected.9
data collected
Clinical data were collected prospectively at participating 
centres, and consisted of presenting signs and symptoms, 
severity of illness, comorbidities, interventions received 
during hospitalisation and clinical outcomes at time of 
discharge. Pathogen testing was according to routine 
diagnostic practices at each participating centre. Organ 
dysfunction for adults was determined through calcu-
lating the Sequential Organ Failure Assessment (SOFA) 
scores.10 For children, an adapted organ dysfunction 
score was used to capture rates of organ dysfunction.11 
Scores were calculated from worst reported component 
data obtained on the first day of admission. Outcomes 
were not censored for the duration of stay. Data collection 
was facilitated through open-access clinical protocols, 
case report forms and web-based data entry of fully 
anonymised data through secure servers.
Analysis
The data were first checked for completeness and 
missing values. Data explorations were performed by 
running frequency checks and descriptive statistics. Data 
on primary study variables (outcomes, exposure metrics 
and derived covariates) were summarised using descrip-
tive statistics, including measures of central tendency 
and dispersion for continuous variables (mean and SD, 
median and IQR) and frequencies with proportions for 
categorical variables. Univariate and multivariate logistic 
regressions were used to assess the association between 
mortality and main a priori proposed risk factors or 
adjusting for potential confounders. All statistical 
significance was assessed at the 5% level of significance 
(two-sided p<0.05). Analyses were performed using 
STATA V.14 statistical software. Regions were defined by 
income and geography according to World Bank country 
and lending groups criteria.12
CrITICAl IllneSS due To Severe ACuTe reSPIrATory 
InfeCTIonS
Data were collected from 1 January 2016 until 31 August 
2017, from 682 patients admitted to 95 participating 
hospitals in 20 countries (see table 1 and figure 1). There 
was a bimodal distribution of age, with the majority of the 
sample children less than 10 years of age (30.0%) and 
those above 60 (39.9%) years (27.7%) (see figure 2).
The overall mortality was 9.5%. The lowest case fatality 
proportion was in children under 5 years (1%). The 
highest case fatality proportions were in adults over 60 
years: 18.4% mortality in patients aged 60–79 years and 
18.9% in those >80 years. Mortality in low-income/
low-middle-income countries was 4% (12 of 302) and 
was 14% (53 of 380) in high-income countries. Mortality 
varied between geographical regions, with East Asia and 
Pacific at 10.2%, Sub-Saharan Africa 4.3%, South Asia 
at 0%, North America 13.6%, and Europe and Central 
Asia 14.3%. The availability of higher level care in inten-
sive care-type settings was variable across regions, with 
access to ventilators absent in eight sites in low-income/
low-middle-income countries. This possibly explains 
the unexpected variability in mortality, where less-sick 
patients were enrolled in Sub-Saharan Africa, given the 
lack of formal intensive care units in the region.
CrITICAl CAre InTervenTIonS
When examining interventions used, patients in East Asia 
(50.7%), North America (49.3%) and Europe (35.6%) 
had higher frequencies of invasive mechanical ventila-
tion compared with patients in South Asia (4.4%) and 
Sub-Saharan Africa (14.3%). Dialysis was received in 0% 
in Sub-Saharan Africa and Latin America and the Carib-
bean, 8.3% in Europe and Central Asia, 9.3% in North 
America, and 6.7% in East Asia and Pacific, although with 
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Table 1 Demographics of included patients (n=682)
Characteristics
Age (median) 49 (IQR 3–70)
Female (%) 44.5
Duration of symptoms before hospitalisation 
(days) (n=682)
3 (IQR 1–5)
Number of listed comorbidities (%)
  0 473 (69.4)
  1 76 (11.1)
  2 72 (10.6)
  3 34 (5.0)
  4+ 27 (4.0)
Income group (%)
  Low income 181 (26.5)
  Lower middle income 121 (17.7)
  Upper middle income 3 (0.2)
  High income 377 (55.3)
Geographical group (%)
  Sub-Saharan Africa 188 (27.6)
  East Asia and Pacific 206 (30.2)
  South Asia 35 (5.1)
  North America 184 (27.0)
  Europe and Central Asia 63 (9.2)
  Middle East and North Africa 3 (0.4)
  Latin America and the Caribbean 3 (0.4)
Age group (%)
  0–10 205 (30.0)
  11–20 24 (3.5)
  21–30 30 (4.4)
  31–40 32 (4.6)
  41–50 52 (7.6)
  51–60 63 (9.2)
  61–70 103 (15.1)
  71–80 80 (11.7)
  >80 83 (12.1)
Figure 1 Countries where there are SPRINT-SARI data 
collection sites, by numbers of patients recruited. SPRINT-
SARI, Short Period prevalence Study of Severe Acute 
Respiratory Infection.
Figure 2 Age and case fatality proportion distribution of 
included patients.
small sample sizes and variable availabilities of interven-
tions.
Severe ACuTe reSPIrATory InfeCTIon PATHogenS
The proportion of patients without a documented infec-
tious aetiology was 66.9% (456 of 682), of whom 7.9% 
(36 of 456) died, as defined as no pathogen was deemed 
causative by the clinical team. Complete diagnostic 
testing was not available in many of the regions, with no 
viral testing used in low-income or low-middle-income 
regions; most of the patients with a documented infection 
were from high-income settings. The most commonly 
diagnosed pathogen was influenza virus (11.6%, 77 
of 663). Respiratory syncytial virus was identified in 19 
patients (2.7%), with <1% of patients with coronavirus 
(0.92%, 6 of 655) and none with Middle East respiratory 
syndrome-coronavirus in this cohort. Bacterial infections 
were identified in 25 of 682 patients (3.6%), with Strep-
tococcus pneumoniae being the most frequently isolated 
bacterial pathogen in respiratory sampling (n=8).
Pathogen-specific disease burden has been examined 
by a number of other groups.13 14 However, our finding 
that the majority of critically ill patients with SARI have 
no diagnosed microbial aetiology reinforces the need for 
syndrome-based, in addition to pathogen-based, surveil-
lance for critically ill patients. This is especially true 
given the lack of relevant diagnostic testing in much of 
the world, which impacted the proportion of patients 
without identified pathogens.15 The availability of global 
data and collaboration is essential, given the likely inter-
national nature of future outbreaks and requirements for 
pre-established coordination efforts.16
The lack of a dedicated sampling protocol clearly 
impacts on interpretation of those findings. Future work 
should focus on optimising hospital sampling strategies 
to better understand global SARI disease; the lack of SARI 
pathogen-specific diagnostics on recently released Essen-
tial Diagnostic Lists exemplifies the lack of clarity on best 
testing strategies.17 Regional SARI surveillance data have 
been published from a variety of countries18 19; while we 
have yet to completely avoid site selection bias through 
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Figure 3 Hospital mortality and Sequential Organ Failure 
Assessment (SOFA) scores (n=560).
Figure 4 Sequential Organ Failure Assessment (SOFA) 
score by region (n=560).
Table 2 Multivariable logistic regression for mortality
Characteristics
SOFA score OR P values Lower CI Upper CI
0–3 Ref
4–7 3.57 0.04 1.082 11.813
8–11 2.95 0.14 0.711 12.230
12+ 12.74 0.001 2.864 56.694
Age 1.03 0.001 1.013 1.049
Gender
  Female Ref
  Male 1.75 0.17 0.783 3.927
Comorbidities
  0 Ref
  1 0.60 0.47 0.144 2.453
  2 1.82 0.29 0.599 5.509
  3 3.36 0.08 0.859 13.152
  4+ 3.41 0.08 0.861 13.486
Length of stay (days)
  0 Ref
  1–7 1.29 0.68 0.388 4.298
  8–14 1.72 0.50 0.353 8.330
  15+ 3.53 0.09 0.842 14.828
Ref, reference; SOFA, Sequential Organ Failure Assessment.
the availability of reporting hospitals, the data collection 
tools used help reduce the risk of bias from individual 
patient selection or pathogen-specific attribution.
SeverITy of IllneSS due To Severe ACuTe reSPIrATory 
InfeCTIonS
Increasing SOFA score on presentation was associated 
with increasing mortality (27% increase in mortality 
for every additional SOFA score point; figure 3). The 
highest organ dysfunction scores were in patients in 
the East Asia and Pacific (57.5% having scores between 
8–11% and 48%, with scores of more than 12) and 
North America (35% having scores between 8–11% and 
24%, with scores of more than 12; figure 4). In children, 
full data on the adapted SOFA score were available in 
only 122 of 220 patients aged less than 10 years, with 
only 2 dying, leading to an inability to perform associ-
ation studies between organ dysfunction and hospital 
mortality. Missing complete data for organ dysfunction 
(n=122) were exclusively focused on lower income 
regions, with greater missing data among children.
Univariate and multivariate logistic regressions were 
used to assess the association between mortality and 
main a priori proposed risk factors or adjusting for 
potential confounders (table 2). We identified that 
SOFA score at admission and increasing age were 
independent predictors of hospital mortality across all 
age groups, where SOFA scores were available. After 
adjusting for potential confounders, increasing SOFA 
score was associated with increased mortality, when 
compared with those with a SOFA score ≤3: SOFA 4–7 
(OR=3.57 (95% CI 1.08 to 11.81), p=0.04), SOFA 8–11 
(OR=2.95 (95% CI 0.71 to 12.23), p=0.14) and SOFA 
≥12 (OR=12.74 (95% CI 2.86 to 56.69), p=0.001). 
There was a 3% increased risk of mortality for every 
yearly increase in age (adjusted OR=1.03 (95% CI 1.01 
to 1.05), p<0.001). Analysis by year showed no signifi-
cant differences between analyses restricted to 2016 or 
2017 seasons.
The variability in case fatality proportions in our 
data set, particularly among children, in addition 
to patient-specific variables, is likely due to a variety 
of factors, including intensive care unit admission 
criteria,20 the availability of interventions21 and the 
presence of reporting bias in this convenience sample, 
particularly as it relates to the sparse data sources for 
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acute care in lower income regions and the known 
disease burden in those regions.1 The stepwise increase 
in mortality by age in our data set reflects this surpris-
ingly low mortality in the <5-year-old cohort. The lack 
of complete severity-of-illness data from lower income 
regions impedes the ability to effectively understand 
this counterintuitive result.
from loCAl To globAl dATA on Severe ACuTe 
reSPIrATory InfeCTIonS
The global SPRINT-SARI programme has a primary 
purpose of testing the clinical research infrastructure 
and network logistics in varied settings. We demon-
strated that presentation, management and outcomes 
for patients with SARI vary substantially according to 
global region. The implications of this variation are 
large, and suggest a need for ongoing, prospective data 
collection at a global scale to ensure a better under-
standing of patient characteristics, specific SARI risk 
factors and the importance of a reliable risk adjustment 
method for international comparative studies. Further, 
the use of organ dysfunction, as measured by a SOFA 
score collected on presentation for critically ill patients 
with SARI in disparate settings, appears promising. This 
deserves further work for risk stratification and early 
outbreak severity predictions, particularly in children 
where our data are limited.
Given previously documented variability in applica-
tion of case definitions and to different care areas (eg, 
hospital wards, intensive care units, emergency depart-
ments), differential inclusion of patients with SARI is 
an ongoing risk during outbreaks, emphasising the 
need for standardised operating procedures for clin-
ical data reporting.22 We have compiled standardised 
open-access tools at  isaric. tghn. org/ sprint- sari to assist 
in this goal. The data reported in this manuscript serve 
to demonstrate the tools; however, without a truly 
representative sample of hospitals and regions, accu-
rate comparisons cannot be made.
lImITATIonS
There are a number of further limitations to this work. 
The first is the nature of the data collected. Given its 
primary objective of being a research preparedness 
exercise, data verification audits were not exhaus-
tively performed, and small numbers in some regions 
may lead to unstable proportions during compari-
sons. The patients that were enrolled in the study may 
not be representative of all critically ill patients with 
SARI, based on the period of data collected and loca-
tion of participating hospitals. Second is the lack of a 
formal denominator to assess the impact of SARI on 
hospital-level or population-level burden of disease, or 
to generate estimates of disease incidence. Capturing 
hospital-wide activity requires substantially larger 
research resources at participating institutions, and 
there is variation as to the screening processes present 
at participating institutions. Third, integrating alter-
nate patient-centred outcomes such as quality of life 
or functional status on discharge23 24 would provide 
valuable data; however, this data collection is beyond 
the scope of this work and will be further integrated 
as programmes continue to scale. Given the mostly 
unfunded nature of this work at the site level, these 
expansions can only occur with established operational 
support. Finally, the availability and definitions of 
intensive care units are variable across regions, and this 
impacts any discussion on interventions received, such 
as dialysis or mechanical ventilation.25
ConCluSIonS
We have shown that it is feasible for a global network of 
hospitals to collect standardised clinical data variables 
on critically ill adults and children with SARI. While 
severity of illness and age are associated with mortality, 
we have also highlighted substantial variability in path-
ogens, management strategies and clinical outcomes 
according to global regions. This emphasises the 
importance of collecting a globally applicable severity 
of illness score at admission for adults and children in 
order to perform valid international comparative studies 
of patients with SARI and for future outbreak severity 
assessments. Future work in documenting SARI care and 
outcomes around the world requires ongoing, stand-
ardized prospective data collection in varied regions, 
particularly among children and other vulnerable 
populations.
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